10,838 Shares in Mesa Laboratories, Inc. $MLAB Acquired by Globeflex Capital L P

Globeflex Capital L P bought a new stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 10,838 shares of the medical instruments supplier’s stock, valued at approximately $958,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Boston Partners increased its position in shares of Mesa Laboratories by 86.6% during the fourth quarter. Boston Partners now owns 213,376 shares of the medical instruments supplier’s stock worth $16,752,000 after purchasing an additional 99,019 shares in the last quarter. Royce & Associates LP boosted its position in shares of Mesa Laboratories by 3.2% in the 4th quarter. Royce & Associates LP now owns 153,352 shares of the medical instruments supplier’s stock worth $12,038,000 after purchasing an additional 4,794 shares in the last quarter. Kennedy Capital Management LLC boosted its position in shares of Mesa Laboratories by 19.0% in the 4th quarter. Kennedy Capital Management LLC now owns 144,606 shares of the medical instruments supplier’s stock worth $11,352,000 after purchasing an additional 23,060 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its position in shares of Mesa Laboratories by 15.1% in the 4th quarter. Diamond Hill Capital Management Inc. now owns 141,973 shares of the medical instruments supplier’s stock worth $11,145,000 after purchasing an additional 18,592 shares in the last quarter. Finally, Millennium Management LLC grew its stake in Mesa Laboratories by 131.9% during the 3rd quarter. Millennium Management LLC now owns 133,817 shares of the medical instruments supplier’s stock worth $8,967,000 after buying an additional 76,107 shares during the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Mesa Laboratories

In other news, CAO Lyndsey Elizabeth Crennen sold 442 shares of Mesa Laboratories stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $39,559.00. Following the completion of the transaction, the chief accounting officer directly owned 2,020 shares of the company’s stock, valued at $180,790. The trade was a 17.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO John Sakys sold 2,827 shares of Mesa Laboratories stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $253,016.50. Following the transaction, the chief financial officer directly owned 19,785 shares of the company’s stock, valued at approximately $1,770,757.50. This trade represents a 12.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 8,277 shares of company stock valued at $770,122. 4.90% of the stock is owned by company insiders.

Mesa Laboratories Stock Performance

MLAB opened at $98.57 on Thursday. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78. The firm has a 50 day moving average of $100.72 and a two-hundred day moving average of $93.91. Mesa Laboratories, Inc. has a 12-month low of $55.45 and a 12-month high of $113.99. The firm has a market capitalization of $544.11 million, a PE ratio of 82.14 and a beta of 0.93.

Mesa Laboratories (NASDAQ:MLAB) last issued its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.The company had revenue of $63.72 million during the quarter, compared to analysts’ expectations of $65.21 million. During the same quarter in the previous year, the company earned ($1.31) EPS.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be issued a $0.16 dividend. The ex-dividend date of this dividend is Monday, August 31st. This represents a $0.64 dividend on an annualized basis and a yield of 0.6%. Mesa Laboratories’s payout ratio is presently 53.33%.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $94.00.

Mesa Laboratories Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.